Catheter Precision Enters Distribution Agreement with FuMedica AG to Bring LockeT to Switzerland
Catheter Precision (NYSE/American: VTAK) announced a distribution agreement with FuMedica AG to introduce the LockeT suture retention device to hospitals and clinics across Switzerland, effective October 16, 2025. LockeT is described as a tool to simplify and secure closure of vascular access sites after cardiac procedures, aimed at electrophysiology labs and interventional suites. FuMedica AG will leverage its Swiss clinical relationships and support capabilities to promote LockeT as part of Catheter Precision’s European expansion.
Catheter Precision (NYSE/American: VTAK) ha annunciato un accordo di distribuzione con FuMedica AG per introdurre il dispositivo di ritenzione dei fili di sutura LockeT negli ospedali e nelle cliniche di tutta la Svizzera, con effetto dal 16 ottobre 2025. LockeT è descritto come uno strumento per semplificare e garantire la chiusura dei siti di accesso vascolare dopo procedure cardiache, mirato ai laboratori di elettrofisiologia e alle sale interventistiche. FuMedica AG farà leva sulle sue relazioni cliniche Svizzere e sulle capacità di supporto per promuovere LockeT nell’ambito dell’espansione europea di Catheter Precision.
Catheter Precision (NYSE/American: VTAK) anunció un acuerdo de distribución con FuMedica AG para introducir el dispositivo de retención de suturas LockeT en hospitales y clínicas de toda Suiza, con efecto a partir del 16 de octubre de 2025. LockeT se describe como una herramienta para simplificar y asegurar el cierre de los sitios de acceso vascular tras procedimientos cardíacos, dirigida a laboratorios de electrofisiología y salas intervencionistas. FuMedica AG aprovechará sus relaciones clínicas en Suiza y sus capacidades de apoyo para promover LockeT como parte de la expansión europea de Catheter Precision.
Catheter Precision (NYSE/American: VTAK)은 FuMedica AG와 유통 계약을 체결하여 LockeT 봉합 보존 장치를 스위스 전역의 병원과 클리닉에 도입하며 2025년 10월 16일부터 시행됩니다. LockeT는 심혈관 시술 후 혈관 접근 부위의 폐쇄를 단순화하고 고정하기 위한 도구로 설명되며, 전기생리학 실험실과 중재실을 대상으로 합니다. FuMedica AG는 스위스의 임상 인맥과 지원 능력을 활용하여 LockeT를 Catheter Precision의 유럽 확장의 일환으로 홍보할 것입니다.
Catheter Precision (NYSE/American: VTAK) a annoncé un accord de distribution avec FuMedica AG pour introduire le dispositif de rétention de suture LockeT dans les hôpitaux et cliniques de toute la Suisse, à effet à partir du 16 octobre 2025. LockeT est décrit comme un outil visant à simplifier et sécuriser la fermeture des sites d’accès vasculaire après des procédures cardiaques, destiné aux laboratoires d'électrophysiologie et aux salles interventionnelles. FuMedica AG tirera parti de ses relations cliniques suisses et de ses capacités de soutien pour promouvoir LockeT dans le cadre de l’expansion européenne de Catheter Precision.
Catheter Precision (NYSE/American: VTAK) gab bekannt, dass sie mit FuMedica AG eine Vertriebsvereinbarung getroffen haben, um das LockeT Nahtretentionsgerät in Krankenhäuser und Kliniken in der gesamten Schweiz einzuführen, mit Wirkung zum 16. Oktober 2025. LockeT wird als Werkzeug beschrieben, um die Schließung von vaskulären Zugangsstellen nach kardialen Eingriffen zu vereinfachen und zu sichern, gerichtet auf Elektrophysiologielabors und Interventionssäle. FuMedica AG wird seine Schweizer klinischen Beziehungen und Support-Fähigkeiten nutzen, um LockeT als Teil der europäischen Expansion von Catheter Precision zu fördern.
Catheter Precision (NYSE/American: VTAK) أعلنت عن اتفاقية توزيع مع FuMedica AG لتقديم جهاز الاحتفاظ بالخيط الجراحي LockeT إلى المستشفيات والعيادات في جميع أنحاء سويسرا، اعتباراً من 16 أكتوبر 2025. يوصف LockeT بأنه أداة لتبسيط وتأمين إغلاق مواقع الدخول الوعائية بعد الإجراءات القلبية، موجهة إلى مختبرات الفيزيولوجيا الكهربية وغرف التدخل. ستستفيد FuMedica AG من علاقاتها السريرية السويسرية وقدرات الدعم التابعة لها للترويج لـ LockeT كجزء من التوسع الأوروبي لـ Catheter Precision.
Catheter Precision (NYSE/American: VTAK)宣布与 FuMedica AG 签署分销协议向全瑞士的医院和诊所推广 LockeT 缝线保留装置，生效日期为 2025 年 10 月 16 日。LockeT 被描述为一种简化并确保在心脏手术后血管通道处闭合的工具，面向电生理实验室和介入手术室。FuMedica AG 将利用其在瑞士的临床关系和支持能力，将 LockeT 推广为 Catheter Precision 欧洲扩张的一部分。
- None.
- None.
FORT MILL, S.C., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company and a leading developer of innovative solutions for cardiac procedures, is pleased to announce a strategic distribution agreement with FuMedica AG, a premier Swiss medical device distributor. This partnership will introduce Catheter Precision’s LockeT suture retention device to hospitals and clinics across Switzerland.
LockeT is a novel suture retention tool designed to simplify and secure the closure of vascular access sites following cardiac procedures. Its intuitive design and reliable performance have made it a valuable addition to electrophysiology labs and interventional suites worldwide.
FuMedica AG, based in Muri, Switzerland, has a long-standing reputation for excellence in distributing advanced medical technologies, particularly in cardiology, surgery, and intensive care. Their strong relationships with Swiss healthcare providers and commitment to clinical support make them an ideal partner for Catheter Precision’s expansion into the region.
“This agreement marks an exciting milestone in our European growth strategy,” said Fatih Ayoglu, Sales Manager EMEA & APAC at Catheter Precision. “FuMedica’s deep market knowledge and dedication to quality align perfectly with our mission to deliver practical, effective tools that improve procedural outcomes. We’re confident LockeT will be a welcome addition to Swiss cardiac care.”
The partnership reflects Catheter Precision’s ongoing commitment to global collaboration and innovation in cardiac care.
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
About FuMedica AG
FuMedica AG is a Swiss-based distributor of high-quality medical devices, specializing in cardiology, surgery, and intensive care. With a strong presence in Switzerland’s healthcare sector, FuMedica is known for its commitment to clinical excellence and customer support.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
What did Catheter Precision (VTAK) announce on October 16, 2025 about Switzerland?
What is LockeT and how is it intended to be used in Swiss hospitals?
Who is FuMedica AG and what role will it play for VTAK in Switzerland?
Does the announcement include sales targets, pricing, or financial terms for VTAK’s Switzerland deal?
How does this agreement fit Catheter Precision’s (VTAK) broader strategy in Europe?
